FDA Brief

Warning letters Drugs

FDA warning letter to

About Mineral

High riskIssued Apr 7, 2021Posted Apr 8, 2021Center for Drug Evaluation and Research

FDA and FTC warn About Mineral that its Puriton skin products are unapproved drugs with misleading COVID-19 claims.

What happened

FDA reviewed https://aboutmineral.com on March 25, 2021, and FTC reviewed it on March 30, 2021; both also cited linked social media pages. FDA found Puriton topical skin products offered for sale with claims that they mitigate, prevent, treat, diagnose, or cure COVID-19, including a claim that Puriton reduced SARS-CoV-2 by more than 99.8% in a lab test. FDA said these are unapproved new drugs and misbranded drugs—sold without FDA approval and with labeling that violates the law.

What FDA found

  1. FDA says the products are unapproved new drugs because they are sold with COVID-19 claims without FDA approval.

    FD&C Act section 505(a), 21 U.S.C. § 355(a)
  2. FDA says the products are misbranded, a labeling violation, because they make COVID-19 claims for an unapproved use.

    FD&C Act section 502, 21 U.S.C. § 352
  3. FDA says introducing these products into interstate commerce is prohibited.

    FD&C Act sections 301(a) and (d), 21 U.S.C. § 331(a) and (d)
  4. FTC says the company advertised that Puriton can prevent, treat, or cure COVID-19 without competent and reliable scientific evidence, including well-controlled human studies.

    FTC Act, 15 U.S.C. 41 et seq.
  5. FTC notes that deceptive COVID-19 treatment, cure, prevention, or mitigation claims can carry civil penalties.

    COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260

What FDA wants

FDA asks the company to take immediate action to stop selling unapproved and unauthorized COVID-19 products and, within 48 hours, email COVID-19-Task-Force-CDER@fda.hhs.gov with the specific steps taken, steps to prevent recurrence, and related documentation. FTC also asks for an email to Richard Cleland at rcleland@ftc.gov within 48 hours describing actions to address its concerns.

Who should pay attention

  • online sellers making COVID-19 health claims
  • brands using social media to promote topical or spray products
  • marketplaces and retailers listing unapproved COVID-19 products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk